Rocky road continues at Biogen
Cambridge drug maker’s top scientist leaving
By 
FOR CAMBRIDGE-BASED Biogen, it’s been the best of times and the worst of times. The biotech powerhouse saw its Alzheimer’s drug Aduhelm approved in June by the Food and Drug Administration. The first new Alzheimer’s therapy in nearly 20 years, the drug looked poised to become a blockbuster treatment that would reap billions in sales(...)